Biogen
BIIB BiotechNeuroscience-focused biotech with MS portfolio (Tecfidera, Tysabri) and controversial Alzheimer's drug Leqembi. Pioneer in neurological diseases.
FDA Novel Drug Designations
(2016-2023)See 6 novel approvals →
Biogen at a Glance
- Leading 5 drug targets across portfolio
- Fast trial execution (16 months median completion)
Biogen's Key Drugs
Biogen's core commercial portfolio centers on SPINRAZA, VUMERITY, TECFIDERA, spanning Neurology and Immunology — its most strategically important drugs approved in the last 15 years.
Spinal muscular atrophy (SMA) in pediatric patients
Clinically isolated syndrome
Clinically isolated syndrome
Friedreich's Ataxia
Multiple Sclerosis
Biogen's Recent FDA Approvals
New NDA/BLA approvals for Biogen over the last two years — novel drugs only, excluding generics and label supplements.
Biogen's Therapeutic Areas
Biogen's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Immunology, across 4 biologic and 6 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Biogen's Top Competitors
Biogen's closest competitors by therapeutic-area and drug-target overlap include Sanofi, Eli Lilly, and Roche. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Biogen Pipeline Snapshot
Biogen has 149 active clinical programs from ClinicalTrials.gov — 45 Phase 3, 42 Phase 2 and 62 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 34/76 completed
- • Speed: 16 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges